ArticleThe Journal of allergy and clinical immunology2007
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.
Article in The Journal of allergy and clinical immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 401 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficiency of Bronchial Thermoplasty on Dynamic Hyperinflation in Uncontrolled Severe Asthma
A Clinical Interventional Study Into Airways Disease Case Finding and Complex Case Management
Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics With/Out Chronic Rhinosinusitis With Nasal Polyps (CRSwNP). Can Shedding of Epithelial Barrier Proteins be Used as Biomarker in Severe Asthma With/Out CRSwNP Management?
Who cites it
401 citing papers in PubMed, 1 synthesis or guideline pooled it, 928 citations in OpenAlex.
- Benralizumab in severe eosinophilic asthma: a comprehensive systematic review and meta-analysis of randomized controlled trials evaluating lung function, asthma control, and safety outcomes.Systematic reviews · 2026Pooled it
- Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants.Pharmacology research & perspectives · 2023Trial
- Trial
- Trial
- Development and initial validation of the Asthma Severity Scoring System (ASSESS).The Journal of allergy and clinical immunology · 2020Trial
- Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations.American journal of respiratory and critical care medicine · 2017Trial
- Association Between Insomnia and Asthma Burden in the Severe Asthma Research Program (SARP) III.Chest · 2016Trial
- Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic.BMC pulmonary medicine · 2016Trial
- Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.BMC pulmonary medicine · 2016Trial
- Estrogen and progesterone decrease let-7f microRNA expression and increase IL-23/IL-23 receptor signaling and IL-17A production in patients with severe asthma.The Journal of allergy and clinical immunology · 2015Trial
- Severe Eosinophilic Asthma: From Immunopathology to Pharmacological Treatment.Journal of clinical medicine · 2026Review
- Current understanding and future directions in severe asthma through artificial intelligence-integrated multi-omic approaches.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Tezepelumab in severe asthma: chest computed tomography assessment of airway remodeling and clinical remission.Frontiers in pharmacology · 2026Article
- Predictive Factors And Treatments Associated with Clinical Remission in Severe Eosinophilic Asthma.Journal of inflammation research · 2026Review
- Sex, hormones, and lung health.Physiological reviews · 2026Review
- Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study.The journal of allergy and clinical immunology. Global · 2026Article
- Article
- αThe journal of allergy and clinical immunology. In practice · 2025Article
- Glucocorticoid Insensitivity: Is It a Question of Time and Place?Biomedicines · 2025Review
- Asthma Phenotypes and Biomarkers.Respiratory care · 2025Review
341 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundSevere asthma causes the majority of asthma morbidity. Understanding mechanisms that contribute to the development of severe disease is important.
objectiveThe goal of the Severe Asthma Research Program is to identify and characterize subjects with severe asthma to understand pathophysiologic mechanisms in severe asthma.
methodsWe performed a comprehensive phenotypic characterization (questionnaires, atopy and pulmonary function testing, phlebotomy, exhaled nitric oxide) in subjects with severe and not severe asthma.
resultsA total of 438 subjects with asthma were studied (204 severe, 70 moderate, 164 mild). Severe subjects with asthma were older with longer disease duration (P < .0001), more daily symptoms, intense urgent health care utilization, sinusitis, and pneumonia (P < or = .0001). Lung function was lower in severe asthma with marked bronchodilator reversibility (P < .001). The severe group had less atopy by skin tests (P = .0007), but blood eosinophils, IgE, and exhaled nitric oxide levels did not differentiate disease severity. A reduced FEV(1), history of pneumonia, and fewer positive skin tests were risk factors for severe disease. Early disease onset (age < 12 years) in severe asthma was associated with longer disease duration (P < .0001) and more urgent health care, especially intensive care (P = .002). Later disease onset (age > or = 12 years) was associated with lower lung function and sinopulmonary infections (P < or = .02).
conclusionSevere asthma is characterized by abnormal lung function that is responsive to bronchodilators, a history of sinopulmonary infections, persistent symptoms, and increased health care utilization. CLINICAL IMPLICATIONS: Lung function abnormalities in severe asthma are reversible in most patients, and pneumonia is a risk factor for the development of severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.